AVB-500 (Washington Univ.)

AVB-500 (Washington Univ.): sourced facts only. name: "Thus, we aimed to determine whether treatment with AVB-500, a selective inhibitor of GAS6-AXL, improves endometrial cancer cell sensitivity to chemotherapy particularly through metabolic changes." [PMID:35588308]; target: "Thus, we aimed to determine whether treatment with AVB-500, a selective inhibitor of GAS6-AXL, improves endometrial cancer cell sensitivity to chemotherapy particularly through metabolic changes." [PMID:35588308]; developer: "Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Barnes Jewish Hospital, Washington University, St. Louis, Missouri." [PMID:35588308]; stage: "We also found that in vivo intraperitoneal models with ARK1 and PUC198 cells had decreased tumor burden when treated with AVB-500 + paclitaxel compared with paclitaxel alone." [PMID:35588308]